On consolidated basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has increased 17.90% to Rs 949.42 crore. Operating profit margin has jumped from 27.08% to 30.75%, leading to 33.87% rise in operating profit to Rs 291.92 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 12.26% to 11.44%. Purchase of finished goods cost fell from 21.91% to 19.28%. Employee cost decreased from 19.05% to 14.64%. Other expenses rose from 17.39% to 20.38%. Other income rose 24.76% to Rs 35.07 crore. PBIDT rose 32.83% to Rs 326.99 crore. Provision for interest fell 71.88% to Rs 0.09 crore. PBDT rose 32.97% to Rs 326.9 crore. Provision for depreciation rose 9.88% to Rs 18.8 crore. Profit before tax grew 34.69% to Rs 308.10 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 78.22 crore, compared to Rs 19.71 crore. Effective tax rate was 25.39% compared to 30.12%. Minority interest was nil in both the periods. Net profit attributable to owners of the company increased 402.80% to Rs 229.88 crore. Promoters’ stake was 75.00% as of 31 December 2024 ,compared to 75.00% as of 31 December 2023 .
For year-to-date (YTD) results analysis.
Net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has increased 9.94% to Rs 2774.84 crore. Operating profit margin has jumped from 25.81% to 30.42%, leading to 29.59% rise in operating profit to Rs 844.17 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 13.65% to 14.38%. Purchase of finished goods cost fell from 23.95% to 20.70%. Employee cost decreased from 18.10% to 15.96%. Other expenses fell from 18.18% to 17.39%. Other income rose 13.46% to Rs 105.25 crore. PBIDT rose 27.58% to Rs 949.42 crore. Provision for interest fell 29.13% to Rs 0.73 crore. PBDT rose 27.66% to Rs 948.69 crore. Provision for depreciation rose 0.95% to Rs 52.07 crore. Profit before tax grew 29.65% to Rs 896.62 crore. Share of profit/loss were nil in both the periods. Provision for tax was expense of Rs 236.6 crore, compared to Rs 150.09 crore. Effective tax rate was 26.25% compared to 27.51%.Minority interest was nil in both the periods. Net profit attributable to owners of the company increased 68.08% to Rs 664.71 crore. Promoters’ stake was 75.00% as of 31 December 2024 ,compared to 75.00% as of 31 December 2023 .
Full year results analysis.
Net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has increased 6.21% to Rs 3453.71 crore. Operating profit margin has jumped from 24.73% to 26.31%, leading to 12.98% rise in operating profit to Rs 908.69 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 13.43% to 15.50%. Purchase of finished goods cost fell from 24.77% to 24.25%. Employee cost decreased from 18.69% to 17.75%. Other expenses fell from 17.83% to 16.66%. Other income rose 21.79% to Rs 122.59 crore. PBIDT rose 13.96% to Rs 1031.28 crore. Provision for interest fell 0.55% to Rs 1.8 crore. Loan funds rose to Rs 18.67 crore as of 31 March 2024 from Rs 15.54 crore as of 31 March 2023. Inventories rose to Rs 525.05 crore as of 31 March 2024 from Rs 459.97 crore as of 31 March 2023. Sundry debtors were higher at Rs 222.06 crore as of 31 March 2024 compared to Rs 192.38 crore as of 31 March 2023. Cash and bank balance declined from Rs 1,155.93 crore as of 31 March 2023 to Rs 1,063.22 crore as of 31 March 2024. Investments rose to Rs 813.22 crore as of 31 March 2024 from Rs 518.29 crore as of 31 March 2023 . PBDT rose 13.99% to Rs 1029.48 crore. Provision for depreciation rose 5.94% to Rs 69.68 crore. Fixed assets declined from Rs 316.18 crore as of 31 March 2023 to Rs 311.65 crore as of 31 March 2024. Intangible assets declined from Rs 34.09 crore to Rs 23.55 crore. Profit before tax grew 14.62% to Rs 959.80 crore. Share of profit/loss were nil in both the periods. Extraordinary items were decreased to Rs -143.61 crore. Provision for tax was expense of Rs 226.23 crore, compared to Rs 228.76 crore. Effective tax rate was 27.72% compared to 27.35%. Minority interest was nil in both the periods. Net profit attributable to owners of the company decreased 2.91% to Rs 589.96 crore. Equity capital stood at Rs 169.41 crore as of 31 March 2024 to Rs 169.41 crore as of 31 March 2023. Per share face Value remained same at Rs 10.00. Promoters’ stake was 75.00% as of 31 March 2024 ,compared to 75.00% as of 31 March 2023 . Cash flow from operating activities increased to Rs 582.00 crore for year ended March 2024 from Rs 484.23 crore for year ended March 2023. Cash flow used in acquiring fixed assets during the year ended March 2024 stood at Rs 31.22 crore, compared to Rs 44.04 crore during the year ended March 2023.
Management Comments :
Mr. Bhushan Akshikar, Managing Director, GlaxoSmithKline
Pharmaceuticals, said, “Our strong third-quarter results reflect our unwavering
commitment to deliver innovative healthcare solutions to patients across India. By
focusing on core brands and accelerating digital transformation through innovative go-to-market strategies, we continue to strengthen our market presence while ensuring
broader access to our medicines and vaccines.”
| Glaxosmithkline Pharmaceuticals : Consolidated Results | | | Quarter ended | Year to Date | Year ended |
|---|
| Particulars | 202412 | 202312 | Var.(%) | 202412 | 202312 | Var.(%) | 202403 | 202303 | Var.(%) |
|---|
| Net Sales (including other operating income) | 949.42 | 805.26 | 17.90 | 2,774.84 | 2,523.91 | 9.94 | 3,453.71 | 3,251.72 | 6.21 | | OPM (%) | 30.75 | 27.08 | 367 bps | 30.42 | 25.81 | 461 bps | 26.31 | 24.73 | 158 bps | | OP | 291.92 | 218.06 | 33.87 | 844.17 | 651.43 | 29.59 | 908.69 | 804.29 | 12.98 | | Other Inc. | 35.07 | 28.11 | 24.76 | 105.25 | 92.76 | 13.46 | 122.59 | 100.66 | 21.79 | | PBIDT | 326.99 | 246.17 | 32.83 | 949.42 | 744.19 | 27.58 | 1,031.28 | 904.95 | 13.96 | | Interest | 0.09 | 0.32 | -71.88 | 0.73 | 1.03 | -29.13 | 1.80 | 1.81 | -0.55 | | PBDT | 326.90 | 245.85 | 32.97 | 948.69 | 743.16 | 27.66 | 1,029.48 | 903.14 | 13.99 | | Depreciation | 18.8 | 17.11 | 9.88 | 52.07 | 51.58 | 0.95 | 69.68 | 65.77 | 5.94 | | PBT | 308.10 | 228.74 | 34.69 | 896.62 | 691.58 | 29.65 | 959.8 | 837.37 | 14.62 | | Share of Profit/(Loss) from Associates | 0 | 0 | - | 0 | 0 | - | 0 | 0 | - | | PBT before EO | 308.1 | 228.74 | 34.69 | 896.62 | 691.58 | 29.65 | 959.8 | 837.37 | 14.62 | | EO Income | 0 | -163.31 | - | 4.69 | -146.01 | LP | -143.61 | -0.97 | -14,705.20 | | PBT after EO | 308.1 | 65.43 | 370.88 | 901.31 | 545.57 | 65.21 | 816.19 | 836.4 | -2.42 | | Taxation | 78.22 | 19.71 | 296.85 | 236.6 | 150.09 | 57.64 | 226.23 | 228.76 | -1.11 | | PAT | 229.88 | 45.72 | 402.80 | 664.71 | 395.48 | 68.08 | 589.96 | 607.64 | -2.91 | | Minority Interest (MI) | 0 | 0 | - | 0 | 0 | - | 0 | 0 | - | | Net profit | 229.88 | 45.72 | 402.80 | 664.71 | 395.48 | 68.08 | 589.96 | 607.64 | -2.91 | | P/(L) from discontinued operations net of tax | 0 | 0 | - | 0 | 0 | - | 0 | 3.05 | - | | Net profit after discontinued operations | 229.88 | 45.72 | 402.80 | 664.71 | 395.48 | 68.08 | 589.96 | 610.69 | -3.39 | | EPS (Rs)* | 13.57 | 9.43 | 43.83 | 39.03 | 29.59 | 31.90 | 40.95 | 35.91 | 14.04 | | | * EPS is on current equity of Rs 169.41 crore, Face value of Rs 10, Excluding extraordinary items. | | # EPS is not annualised | | bps : Basis points | | EO : Extraordinary items | | Figures in Rs crore | | Source: Capitaline Corporate Database |
|
|